Galapagos NV: Galapagos initiates Phase 3 program with filgo

OLINGUITO Phase 3 program in adults with axial spondyloarthritis (AxSpA) to include two parallel studies to investigate the efficacy and safety of filgotinib in patients with active radiographic AxSpA

Related Keywords

Belgium , Bochum , Nordrhein Westfalen , Germany , Mechelen , Region Flamande , United Kingdom , Ruhr , Northern Ireland , Craigavon , Japan , Japanese , Great Britain , Van Gijsel , Marieke Vermeersch , Daniele Dambrosio , Xenofon Baraliakos , Elisa Chenailler , Sandra Cauwenberghs , European Union , Linkedin , Japanese Ministry Of Health , University Bochum , Exchange Commission , European Medicines Agency , Gilead Sciences Inc , Twitter , Percentage Of Participants Achieving Spondyloarthritis International Society , Axspa Topline , Ankylosing Spondylitis Disease Activity Score , Internal Medicine , Ruhr University Bochum , Coordinating Investigator , Danieled Ambrosio , Therapeutic Area Head , European Summary , Product Characteristics , Great Britain Summary , Northern Ireland Summary , Japanese Ministry , Gilead Sciences , Annual Report , Ankylosing Spondylitis , Der Heijde , Galapagos , Nitiates , Hase , Program , Filgotinib , Patients , Ctive , Coaxial , Spondyloarthritis ,